SYNCOMF2024-07-012024-09-30 SYNCOMF2024-07-012024-09-30 SYNCOMF2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member SYNCOMF2024-09-30 SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue03Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults03Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SYNCOMF2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2024-04-01 2025-03-31 2024-11-11 2024-11-04 INR Lakhs Half yearly 16:00:00 17:15:00 2024-11-11 2024-11-11 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Standalone 1014925000.00 41835000.00 1056760000.00 685757000.00 126024000.00 -156083000.00 124039000.00 1622000.00 13000000.00 115889000.00 910248000.00 146512000.00 -24000.00 146488000.00 34855000.00 2133000.00 36988000.00 0.00 109500000.00 0.00 0.00 0.00 0.00 109500000.00 39188000.00 148688000.00 0.00 0.00 940000000.00 1 0.16 0.16 0.00 0.00 0.16 0.16 0.00 0.00 0.00 Multi segment 2024-04-01 2024-09-30 Unaudited Standalone 1873568000.00 64632000.00 1938200000.00 1216070000.00 166632000.00 -182412000.00 232515000.00 5487000.00 26000000.00 226427000.00 1690719000.00 247481000.00 -24000.00 247457000.00 59232000.00 2439000.00 61671000.00 0.00 185786000.00 0.00 0.00 0.00 0.00 185786000.00 66781000.00 252567000.00 0.00 0.00 940000000.00 1 0.27 0.27 0.00 0.00 0.27 0.27 0.00 0.00 0.00 other expenses 115889000.00 other expenses 226427000.00 699922000.00 14211000.00 473344000.00 0.00 472000.00 0.00 0.00 0.00 55869000.00 0.00 0.00 7262000.00 63131000.00 0.00 4956000.00 1256036000.00 450531000.00 801238000.00 866276000.00 2173000.00 116316000.00 54259000.00 34014000.00 1874276000.00 0.00 113096000.00 2437903000.00 0.00 0.00 3693939000.00 940000000.00 2177084000.00 3117084000.00 3117084000.00 0.00 0.00 9252000.00 9252000.00 37044000.00 52206000.00 0.00 0.00 98502000.00 136721000.00 233667000.00 21957000.00 392345000.00 55157000.00 30851000.00 0.00 0.00 478353000.00 0.00 0.00 576855000.00 3693939000.00 Pharmaceuticals Drugs & Formulations 1021843000.00 Renting of Property 9807000.00 Trading of Commodities 25110000.00 Pharmaceuticals Drugs & Formulations 1880376000.00 Renting of Property 19473000.00 Trading of Commodities 38351000.00 1056760000.00 1938200000.00 0.00 0.00 1056760000.00 1938200000.00 Pharmaceuticals Drugs & Formulations 138269000.00 Renting of Property 9001000.00 Trading of Commodities 840000.00 Pharmaceuticals Drugs & Formulations 233805000.00 Renting of Property 17860000.00 Trading of Commodities 1279000.00 148110000.00 252944000.00 1622000.00 5487000.00 0.00 Notes:- 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/11/2024. 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4 The Standalone Statement of Assets and Liabilities as at 30th September, 2024 and the Standalone Statement of Cash Flow is provided as an annexure to this statement. 5 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September 2024. The report does not have any impact on the above results and notes which needs explanation. 6 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 0.00 146488000.00 247457000.00 Pharmaceuticals Drugs & Formulations 3123408000.00 Renting of Property 473345000.00 Trading of Commodities 97186000.00 3693939000.00 0.00 3693939000.00 Pharmaceuticals Drugs & Formulations 543216000.00 Renting of Property 9252000.00 Trading of Commodities 24387000.00 576855000.00 0.00 576855000.00 5487000.00 -239716000.00 65870000.00 0.00 -21927000.00 0.00 0.00 -11326000.00 0.00 91357000.00 0.00 19353000.00 0.00 26000000.00 0.00 -3695000.00 0.00 595000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -64615000.00 0.00 0.00 -132617000.00 114840000.00 0.00 0.00 0.00 59232000.00 0.00 55608000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16440000.00 0.00 127216000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 37980000.00 0.00 -105676000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -579782000.00 0.00 0.00 0.00 0.00 5487000.00 0.00 4006000.00 -581263000.00 -631331000.00 0.00 -631331000.00 633505000.00 2174000.00 0.00 0.00 Amount of items that will be reclassified to profit and loss 39188000.00 Amount of items that will be reclassified to profit and loss 66781000.00 39188000.00 66781000.00 0.00 0.00